sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.
|
lamivudine
|
paroxetine
|
NONE
|
Efavirenz_ddi.xml
|
DDI-DrugBank.d531.s90
|
DDI-DrugBank.d531.s90.p58
|
In addition, under the influence of sympatholytic medicinal products such as beta-blockers, clonidine, guanethidine, and reserpine, the signs of hypoglycemia may be reduced or absent.
|
clonidine
|
guanethidine
|
NONE
|
Insulin Glargine recombinant_ddi.xml
|
DDI-DrugBank.d527.s5
|
DDI-DrugBank.d527.s5.p3
|
Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.
|
omeprazole
|
erythromycin
|
NONE
|
Cilostazol_ddi.xml
|
DDI-DrugBank.d358.s1
|
DDI-DrugBank.d358.s1.p0
|
Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
|
multivitamins
|
Pronestyl
|
NONE
|
Bentiromide_ddi.xml
|
DDI-DrugBank.d537.s0
|
DDI-DrugBank.d537.s0.p96
|
however, patients with moderate to severe cardiovascular disease or those taking nitrate therapy are at increased risk for potentially serious cardiovascular adverse effects with sildenafil therapy.
|
nitrate
|
sildenafil
|
EFFECT
|
11219477.xml
|
DDI-MedLine.d42.s9
|
DDI-MedLine.d42.s9.p0
|
Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors, including lisinopril.
|
NSAIDs
|
lisinopril
|
EFFECT
|
Lisinopril_ddi.xml
|
DDI-DrugBank.d334.s7
|
DDI-DrugBank.d334.s7.p1
|
Most of the above effects concerning diuretics have been attributed, at least in part, to mechanisms involving inhibition of prostaglandin synthesis by INDOCIN.
|
diuretics
|
INDOCIN
|
EFFECT
|
Indomethacin_ddi.xml
|
DDI-DrugBank.d82.s32
|
DDI-DrugBank.d82.s32.p0
|
and disulfiram When amitriptyline HCl is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required.
|
disulfiram
|
epinephrine
|
NONE
|
Amitriptyline_ddi.xml
|
DDI-DrugBank.d99.s18
|
DDI-DrugBank.d99.s18.p3
|
Tricyclic antidepressants (amitriptyline, imipramine, nortriptyline): Metabolism may be inhibited by combination hormonal contraceptives, increasing plasma levels of antidepressant;
|
imipramine
|
combination hormonal contraceptives
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s41
|
DDI-DrugBank.d485.s41.p10
|
However, it has been established that acitretin interferes with the contraceptive effect of microdosed progestin minipill preparations.
|
acitretin
|
progestin
|
EFFECT
|
Acitretin_ddi.xml
|
DDI-DrugBank.d353.s5
|
DDI-DrugBank.d353.s5.p0
|
Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.
|
ketoconazole
|
paroxetine
|
NONE
|
Aripiprazole_ddi.xml
|
DDI-DrugBank.d509.s8
|
DDI-DrugBank.d509.s8.p2
|
Adrenergic Agents:Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents.
|
ZYVOX
|
dopaminergic agents
|
EFFECT
|
Linezolid_ddi.xml
|
DDI-DrugBank.d441.s2
|
DDI-DrugBank.d441.s2.p6
|
Ritonavir significantly prolonged the half-life of vardenafil to 26 hours.
|
Ritonavir
|
vardenafil
|
MECHANISM
|
Vardenafil_ddi.xml
|
DDI-DrugBank.d198.s14
|
DDI-DrugBank.d198.s14.p0
|
MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor phenelzine .
|
MAO Inhibitors
|
MAO inhibitor
|
NONE
|
Bupropion_ddi.xml
|
DDI-DrugBank.d5.s19
|
DDI-DrugBank.d5.s19.p1
|
Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
|
diazepam
|
insulin
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s4
|
DDI-DrugBank.d411.s4.p313
|
At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL).
|
methotrexate
|
methotrexate
|
NONE
|
Rofecoxib_ddi.xml
|
DDI-DrugBank.d210.s21
|
DDI-DrugBank.d210.s21.p4
|
Other antiarrhythmic drugs (eg, quinidine, procainamide, lidocaine, propranolol) have occasionally been used concurrently with Norpace.
|
antiarrhythmic drugs
|
procainamide
|
NONE
|
Disopyramide_ddi.xml
|
DDI-DrugBank.d506.s2
|
DDI-DrugBank.d506.s2.p1
|
Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.
|
VIDEX
|
ciprofloxacin
|
ADVISE
|
Didanosine_ddi.xml
|
DDI-DrugBank.d43.s8
|
DDI-DrugBank.d43.s8.p7
|
Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam, oxazepam, temazepam).
|
hormonal contraceptives
|
oxazepam
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s17
|
DDI-DrugBank.d485.s17.p13
|
Antihypertensive medications, other, especially diazoxide, or preanesthetic and anesthetic agents used in surgery or skeletal-muscle relaxants, nondepolarizing, used in surgery
|
Antihypertensive medications
|
skeletal-muscle relaxants
|
NONE
|
Hydroflumethiazide_ddi.xml
|
DDI-DrugBank.d17.s6
|
DDI-DrugBank.d17.s6.p2
|
Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
|
SPRYCEL
|
clarithromycin
|
MECHANISM
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s1
|
DDI-DrugBank.d48.s1.p3
|
Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.
|
charcoal
|
Acarbose
|
MECHANISM
|
Acarbose_ddi.xml
|
DDI-DrugBank.d536.s4
|
DDI-DrugBank.d536.s4.p8
|
Consequently, estazolam should be avoided in patients receiving ketoconazole and itraconazole, which are very potent inhibitors of CYP3A.
|
estazolam
|
itraconazole
|
ADVISE
|
Estazolam_ddi.xml
|
DDI-DrugBank.d338.s6
|
DDI-DrugBank.d338.s6.p1
|
Ethoxzolamide may increase the action of tricyclics, amphetamines, procainamide, and quinidine.
|
Ethoxzolamide
|
amphetamines
|
EFFECT
|
Ethoxzolamide_ddi.xml
|
DDI-DrugBank.d286.s0
|
DDI-DrugBank.d286.s0.p1
|
No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with entacapone without coadministered levodopa/dopa-decarboxylase inhibitor.
|
imipramine
|
entacapone
|
NONE
|
Entacapone_ddi.xml
|
DDI-DrugBank.d455.s11
|
DDI-DrugBank.d455.s11.p4
|
In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.
|
non-steroidal anti-inflammatory agent
|
loop diuretics
|
EFFECT
|
Amiloride_ddi.xml
|
DDI-DrugBank.d356.s4
|
DDI-DrugBank.d356.s4.p0
|
The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.
|
Aprepitant
|
Aprepitant
|
NONE
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s14
|
DDI-DrugBank.d382.s14.p8
|
Close supervision and careful adjustment of dosage are required when Anafranil is administered with anticholinergic or sympathomimetic drugs.
|
Anafranil
|
anticholinergic
|
ADVISE
|
Clomipramine_ddi.xml
|
DDI-DrugBank.d238.s3
|
DDI-DrugBank.d238.s3.p0
|
Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.
|
tiagabine
|
primidone
|
MECHANISM
|
Tiagabine_ddi.xml
|
DDI-DrugBank.d277.s12
|
DDI-DrugBank.d277.s12.p10
|
Cholestyramine increases enterohepatic elimination of amiodarone and may reduce its serum levels and t1/2.
|
amiodarone
|
t1
|
NONE
|
Amiodarone_ddi.xml
|
DDI-DrugBank.d143.s56
|
DDI-DrugBank.d143.s56.p2
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Sporanox
|
Prelone
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p605
|
Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
|
bupropion
|
nortriptyline
|
ADVISE
|
Bupropion_ddi.xml
|
DDI-DrugBank.d5.s17
|
DDI-DrugBank.d5.s17.p1
|
(1968, 1970), the higher serum concentrations of penicillins and cephaloridine reached after administration of probenecid are due not only to slower renal elimination but also to an altered distribution in the body.
|
cephaloridine
|
probenecid
|
MECHANISM
|
15830476.xml
|
DDI-MedLine.d29.s2
|
DDI-MedLine.d29.s2.p2
|
Cholestyramine: Cholestyramine binds both T4 and T3 in the intestine, thus impairing absorption of these thyroid hormones.
|
Cholestyramine
|
T3
|
MECHANISM
|
Liothyronine_ddi.xml
|
DDI-DrugBank.d54.s8
|
DDI-DrugBank.d54.s8.p5
|
The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed.
|
phenytoin
|
drugs
|
NONE
|
11206048.xml
|
DDI-MedLine.d60.s2
|
DDI-MedLine.d60.s2.p5
|
On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.
|
ketoconazole
|
bexarotene
|
MECHANISM
|
Bexarotene_ddi.xml
|
DDI-DrugBank.d467.s2
|
DDI-DrugBank.d467.s2.p8
|
Interaction between glycine and glutamate in the development of spontaneous motility in chick embryos.
|
glycine
|
glutamate
|
EFFECT
|
7794883.xml
|
DDI-MedLine.d20.s0
|
DDI-MedLine.d20.s0.p0
|
Pharmacokinetic interaction studies with cetirizine in adults were conducted with pseudoephedrine, antipyrine, ketoconazole, erythromycin and azithromycin.
|
antipyrine
|
ketoconazole
|
NONE
|
Cetirizine_ddi.xml
|
DDI-DrugBank.d393.s0
|
DDI-DrugBank.d393.s0.p9
|
The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
|
SSRI
|
TCA
|
INT
|
Doxepin_ddi.xml
|
DDI-DrugBank.d223.s9
|
DDI-DrugBank.d223.s9.p0
|
Ethosuximide: Amphetamines may delay intestinal absorption of ethosuximide.
|
Amphetamines
|
ethosuximide
|
MECHANISM
|
Lisdexamfetamine_ddi.xml
|
DDI-DrugBank.d158.s13
|
DDI-DrugBank.d158.s13.p2
|
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.
|
platelet inhibitors
|
acetylsalicylic acid
|
NONE
|
Fondaparinux sodium_ddi.xml
|
DDI-DrugBank.d15.s0
|
DDI-DrugBank.d15.s0.p21
|
Caffeine-related adverse effects have occurred in patients consuming caffeine while on therapy with enoxacin.
|
caffeine
|
enoxacin
|
EFFECT
|
Enoxacin_ddi.xml
|
DDI-DrugBank.d395.s5
|
DDI-DrugBank.d395.s5.p2
|
Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.
|
botulinum toxin
|
botulinum toxin
|
EFFECT
|
Botulinum Toxin Type A_ddi.xml
|
DDI-DrugBank.d133.s2
|
DDI-DrugBank.d133.s2.p0
|
PROSTIN E2 may augment the activity of other oxytocic drugs.
|
PROSTIN E2
|
oxytocic drugs
|
EFFECT
|
Dinoprostone_ddi.xml
|
DDI-DrugBank.d2.s0
|
DDI-DrugBank.d2.s0.p0
|
Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and cyclophosphamide).
|
WELLBUTRIN
|
orphenadrine
|
INT
|
Bupropion_ddi.xml
|
DDI-DrugBank.d5.s3
|
DDI-DrugBank.d5.s3.p0
|
Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
|
insulin
|
6-mercaptopurine
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s4
|
DDI-DrugBank.d411.s4.p429
|
Glyburide: The concomitant administration of ciprofloxacin with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.
|
ciprofloxacin
|
glyburide
|
EFFECT
|
Ciprofloxacin_ddi.xml
|
DDI-DrugBank.d123.s3
|
DDI-DrugBank.d123.s3.p4
|
NSAIDs: In in vitro studies, M1 was shown to cause increases ranging from 13 - 50% in the free fraction of diclofenac and ibuprofen at concentrations in the clinical range.
|
NSAIDs
|
diclofenac
|
NONE
|
Leflunomide_ddi.xml
|
DDI-DrugBank.d41.s9
|
DDI-DrugBank.d41.s9.p0
|
When Vardenafil dosing was separated from terazosin 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of Vardenafil experienced a decrease in standing systolic blood pressure below 85 mm Hg.
|
Vardenafil
|
terazosin
|
EFFECT
|
Vardenafil_ddi.xml
|
DDI-DrugBank.d198.s31
|
DDI-DrugBank.d198.s31.p0
|
Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.
|
NSAIDs
|
warfarin
|
ADVISE
|
Diclofenac_ddi.xml
|
DDI-DrugBank.d249.s2
|
DDI-DrugBank.d249.s2.p5
|
In a study in normal volunteers, it was found that chronic concurrent administration of 3.6 g of aspirin per day decreases indomethacin blood levels approximately 20%.
|
aspirin
|
indomethacin
|
MECHANISM
|
Indomethacin_ddi.xml
|
DDI-DrugBank.d82.s3
|
DDI-DrugBank.d82.s3.p0
|
Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other.
|
TCAs
|
SSRIs
|
ADVISE
|
Amitriptyline_ddi.xml
|
DDI-DrugBank.d99.s10
|
DDI-DrugBank.d99.s10.p0
|
Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
|
verapamil
|
digoxin
|
MECHANISM
|
Digoxin_ddi.xml
|
DDI-DrugBank.d450.s2
|
DDI-DrugBank.d450.s2.p15
|
Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied
|
Antizol
|
cimetidine
|
MECHANISM
|
Fomepizole_ddi.xml
|
DDI-DrugBank.d228.s2
|
DDI-DrugBank.d228.s2.p2
|
Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.
|
Diuretic agents
|
lithium
|
MECHANISM
|
Hydrochlorothiazide_ddi.xml
|
DDI-DrugBank.d162.s10
|
DDI-DrugBank.d162.s10.p0
|
INDOCIN can reduce the antihypertensive effects of captopril and losartan.
|
INDOCIN
|
losartan
|
EFFECT
|
Indomethacin_ddi.xml
|
DDI-DrugBank.d82.s35
|
DDI-DrugBank.d82.s35.p1
|
Therefore, dose adjustments of concomitant medications that are predominantly metabolized by CYP2D6 and have a narrow therapeutic index (e.g., flecainide, vinblastine, thioridazine and most tricyclic antidepressants) may be required.
|
thioridazine
|
tricyclic antidepressants
|
NONE
|
Cinacalcet_ddi.xml
|
DDI-DrugBank.d512.s2
|
DDI-DrugBank.d512.s2.p5
|
Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.
|
Sucralfate
|
lomefloxacin
|
MECHANISM
|
Lomefloxacin_ddi.xml
|
DDI-DrugBank.d516.s3
|
DDI-DrugBank.d516.s3.p20
|
Vitamin D3 administration to rachitic chicks was effective in significantly elevating duodenal arsenate absorption, acting primarily to enhance serosal transport.
|
Vitamin D3
|
arsenate
|
MECHANISM
|
2981680.xml
|
DDI-MedLine.d82.s8
|
DDI-MedLine.d82.s8.p0
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
diazoxide
|
miconazole
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p757
|
Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid in combination with DIFFERIN Gel.
|
sulfur
|
DIFFERIN
|
NONE
|
Adapalene_ddi.xml
|
DDI-DrugBank.d370.s1
|
DDI-DrugBank.d370.s1.p2
|
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.
|
azathioprine
|
gold
|
NONE
|
Abatacept_ddi.xml
|
DDI-DrugBank.d297.s2
|
DDI-DrugBank.d297.s2.p46
|
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
|
phenytoin
|
H2-antagonists
|
MECHANISM
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s10
|
DDI-DrugBank.d40.s10.p10
|
Anticoagulants: Flurbiprofen like other nonsteroidal anti-inflammatory drugs, has been shown to affect bleeding parameters in patients receiving anti-coagulants, and serious clinical bleeding has been reported.
|
Anticoagulants
|
anti-coagulants
|
NONE
|
Flurbiprofen_ddi.xml
|
DDI-DrugBank.d529.s2
|
DDI-DrugBank.d529.s2.p2
|
Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.
|
aspirin
|
corticosteroids
|
EFFECT
|
Dexamethasone_ddi.xml
|
DDI-DrugBank.d314.s24
|
DDI-DrugBank.d314.s24.p8
|
Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.
|
Terfenadine
|
ketoconazole
|
MECHANISM
|
Fluvoxamine_ddi.xml
|
DDI-DrugBank.d76.s7
|
DDI-DrugBank.d76.s7.p2
|
Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.
|
volatile inhalation anesthetics
|
ALFENTA
|
MECHANISM
|
Alfentanil_ddi.xml
|
DDI-DrugBank.d8.s3
|
DDI-DrugBank.d8.s3.p0
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
antifungals
|
Nizoral
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p495
|
Central Nervous System Depressants: The concomitant use of DURAGESIC (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
|
fentanyl
|
skeletal muscle relaxants
|
EFFECT
|
Fentanyl_ddi.xml
|
DDI-DrugBank.d170.s5
|
DDI-DrugBank.d170.s5.p31
|
ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors.
|
NSAIDs
|
Angiotensin Converting Enzyme (ACE) inhibitors
|
EFFECT
|
Celecoxib_ddi.xml
|
DDI-DrugBank.d172.s9
|
DDI-DrugBank.d172.s9.p2
|
Ibogaine attenuates, but 18-MC potentiates, the acute locomotor effects of morphine;
|
18-MC
|
morphine
|
EFFECT
|
11085336.xml
|
DDI-MedLine.d110.s9
|
DDI-MedLine.d110.s9.p2
|
Cimetidine is reported to reduce hepatic metabolism of certain tricyclic antidepressants, thereby delaying elimination and increasing steady-state concentrations of these drugs.
|
Cimetidine
|
tricyclic antidepressants
|
MECHANISM
|
Amitriptyline_ddi.xml
|
DDI-DrugBank.d99.s21
|
DDI-DrugBank.d99.s21.p0
|
The Cmax of norethindrone was 13% higher when it was coadministered with gabapentin;
|
norethindrone
|
gabapentin
|
MECHANISM
|
Gabapentin_ddi.xml
|
DDI-DrugBank.d438.s35
|
DDI-DrugBank.d438.s35.p0
|
In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).
|
cisplatin
|
cisplatin
|
NONE
|
Paclitaxel_ddi.xml
|
DDI-DrugBank.d288.s0
|
DDI-DrugBank.d288.s0.p6
|
- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or
|
oxandrolone
|
Winstrol
|
NONE
|
Sulfapyridine_ddi.xml
|
DDI-DrugBank.d179.s3
|
DDI-DrugBank.d179.s3.p25
|
Aspirin: Animal studies wshow that aspirin given with nonsteroidal anti-inflammatory agents, including ibuprofen, yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug.
|
aspirin
|
ibuprofen
|
EFFECT
|
Ibuprofen_ddi.xml
|
DDI-DrugBank.d415.s2
|
DDI-DrugBank.d415.s2.p4
|
Concurrent use of phenothiazines may antagonize the anorectic effect of diethylpropion.
|
phenothiazines
|
diethylpropion
|
EFFECT
|
Diethylpropion_ddi.xml
|
DDI-DrugBank.d352.s4
|
DDI-DrugBank.d352.s4.p0
|
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.
|
indinavir
|
budesonide
|
ADVISE
|
Budesonide_ddi.xml
|
DDI-DrugBank.d144.s1
|
DDI-DrugBank.d144.s1.p17
|
Noncardioselective beta-blockers (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.
|
Noncardioselective beta-blockers
|
guanfacine
|
EFFECT
|
Guanfacine_ddi.xml
|
DDI-DrugBank.d507.s5
|
DDI-DrugBank.d507.s5.p2
|
Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see a href= frova_od.htm#CI CONTRAINDICATIONS).
|
ergotamine
|
FROVA
|
ADVISE
|
Frovatriptan_ddi.xml
|
DDI-DrugBank.d426.s1
|
DDI-DrugBank.d426.s1.p3
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Etonogestrel
|
Fortovase
|
INT
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p26
|
however, no deleterious interactions were seen when ROMAZICON was administered after narcotics, inhalational anesthetics, muscle relaxants and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.
|
anesthetics
|
muscle relaxants
|
NONE
|
Flumazenil_ddi.xml
|
DDI-DrugBank.d234.s1
|
DDI-DrugBank.d234.s1.p5
|
- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.
|
Perhexiline hydrogen maleate
|
Bezalip retard
|
ADVISE
|
Bezafibrate_ddi.xml
|
DDI-DrugBank.d291.s11
|
DDI-DrugBank.d291.s11.p2
|
DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.
|
DOSTINEX
|
metoclopramide
|
ADVISE
|
Cabergoline_ddi.xml
|
DDI-DrugBank.d282.s0
|
DDI-DrugBank.d282.s0.p3
|
The concomitant administration of bosentan and cyclosporine A is contraindicated.
|
bosentan
|
cyclosporine A
|
ADVISE
|
Bosentan_ddi.xml
|
DDI-DrugBank.d289.s12
|
DDI-DrugBank.d289.s12.p0
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
cyclosporin
|
lorazepam
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p418
|
It is recommended that serum lithium levels be monitored frequently if PRINIVIL is administered concomitantly with lithium.
|
PRINIVIL
|
lithium
|
ADVISE
|
Lisinopril_ddi.xml
|
DDI-DrugBank.d334.s20
|
DDI-DrugBank.d334.s20.p2
|
Epidural clonidine may prolong the duration of pharmacologic effects of epidural local anesthetics, including both sensory and motor blockade.
|
clonidine
|
anesthetics
|
EFFECT
|
Clonidine_ddi.xml
|
DDI-DrugBank.d495.s10
|
DDI-DrugBank.d495.s10.p0
|
Alkalinizing agents: Gastrointestinal alkalinizing agents (sodium bicarbonate, etc.) increase absorption of amphetamines.
|
sodium bicarbonate
|
amphetamines
|
MECHANISM
|
Dextroamphetamine_ddi.xml
|
DDI-DrugBank.d236.s4
|
DDI-DrugBank.d236.s4.p0
|
Coumarin Anticoagulants: There have been rare reports of increased prothrombin time in patients taking coumarin anticoagulants to whom nifedipine was administered.
|
coumarin anticoagulants
|
nifedipine
|
EFFECT
|
Nifedipine_ddi.xml
|
DDI-DrugBank.d373.s9
|
DDI-DrugBank.d373.s9.p2
|
Cypermethrin-induced oxidative stress in rat brain and liver is prevented by vitamin E or allopurinol.
|
Cypermethrin
|
vitamin E
|
EFFECT
|
11137320.xml
|
DDI-MedLine.d126.s0
|
DDI-MedLine.d126.s0.p0
|
In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.
|
triamterene
|
dofetilide
|
ADVISE
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s22
|
DDI-DrugBank.d558.s22.p2
|
Nevertheless, the effects of Mefloquine on travelers receiving comedication, particularly diabetics or patients using anticoagulants, should be checked before departure.
|
Mefloquine
|
anticoagulants
|
ADVISE
|
Mefloquine_ddi.xml
|
DDI-DrugBank.d220.s16
|
DDI-DrugBank.d220.s16.p0
|
Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity.
|
Erythromycin
|
theophylline
|
EFFECT
|
Erythromycin_ddi.xml
|
DDI-DrugBank.d397.s0
|
DDI-DrugBank.d397.s0.p0
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
polymyxins
|
lincomycin
|
NONE
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p75
|
In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin, cefazolin, ampicillin, ampicillin/flucoxacillin, ceftazidime, gentamicin, and amphotericin demonstrated no evidence of incompatibility of these antibiotics with EXTRANEAL.
|
ceftazidime
|
gentamicin
|
NONE
|
Icodextrin_ddi.xml
|
DDI-DrugBank.d501.s10
|
DDI-DrugBank.d501.s10.p26
|
Clidinium may decrease the effect of phenothiazines, levodopa, and ketoconazole.
|
Clidinium
|
ketoconazole
|
EFFECT
|
Clidinium_ddi.xml
|
DDI-DrugBank.d322.s1
|
DDI-DrugBank.d322.s1.p2
|
Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by itraconazole, amphotericin B, mycophenolate, nelfinavir, or tacrolimus.
|
CANCIDAS
|
mycophenolate
|
NONE
|
Caspofungin_ddi.xml
|
DDI-DrugBank.d350.s3
|
DDI-DrugBank.d350.s3.p2
|
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital.
|
ketamine
|
Innovar
|
NONE
|
1167743.xml
|
DDI-MedLine.d23.s1
|
DDI-MedLine.d23.s1.p33
|
Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
|
acetaminophen
|
alcohol
|
EFFECT
|
Butalbital_ddi.xml
|
DDI-DrugBank.d559.s1
|
DDI-DrugBank.d559.s1.p11
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.